Skip to main contentSkip to navigation
Sirius Investors

Allogene Therapeutics, Inc. (ALLO) Investment Research Dashboard

About Allogene Therapeutics, Inc. (ALLO) stock analysis

Get live ALLO stock price $1.74, comprehensive Allogene Therapeutics, Inc. stock analysis, charts, news, sentiment, sector analysis, and expert forecast. Real-time ALLO stock data and investment insights.

1.74
4.40%Today
Market Cap
600.57M
Volume
4.86M
52W High
4.46
52W Low
0.98

Loading chart data...

Investment Score

TTM (current)
Unavailable

A systematic tri-factor framework (valuation, quality, momentum) using trailing twelve-month fundamentals and current price momentum—aligned with the full investment score dashboard.

Score unavailable for this asset.

0-39

Defensive posture

40-54

Mixed / wait for confirmation

55-69

Constructive setup

70-100

Attractive zone

Total Score

Value

Cheapness vs fundamentals and cash generation

Quality

Durability of profitability and balance sheet

Momentum

Price trend strength and persistence

Professional usage: treat the score as a ranking and risk-filtering tool, then confirm with earnings revision trend, competitive positioning, and valuation relative to peers before capital allocation.

Company Overview

Allogene Therapeutics, Inc. operates as a clinical-stage immuno-oncology firm dedicated to the creation and commercialization of genetically engineered allogeneic T-cell therapies for the treatment of various cancers. A pivotal product in their devel...

Company Information

CEO
Zachary Roberts
Sector
Healthcare
Industry
Biotechnology
Employees
152

Contact Information

Address
210 East Grand Avenue
Country
US

Investment Analysis & Business Insights

Healthcare
Biotechnology

Investment Highlights

Strong presence in the Healthcare sector with established market position

Lower volatility stock (Beta: 0.46) may provide portfolio stability

Important Investment Considerations

  • All investments carry risk, including potential loss of principal for Allogene Therapeutics, Inc. shareholders
  • Market volatility can significantly impact stock price, especially for smaller companies
  • Sector-specific risks in Healthcare may affect company performance
  • Past performance does not guarantee future results for Allogene Therapeutics, Inc.
  • Investors should consider how Allogene Therapeutics, Inc. fits within their overall portfolio allocation
  • Valuation metrics suggest potential, but require fundamental analysis

Market Cap

600.57M

P/E Ratio (TTM)

-2.26

Beta

0.46

Data Sources & Methodology

Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.

About Healthcare Sector

The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.

Healthcare (1D)

77/100 ⭐⭐⭐⭐⭐

Overall
+0.3%
NYSE
+0.7%
NASDAQ
-0.2%
Sector1D1W1MP/EScore
Financial Services+0.3%+1.5%+2.2%19.1
82/100⭐⭐⭐⭐⭐
Healthcare+0.3%+2.7%+1.5%23.5
77/100⭐⭐⭐⭐⭐
Real Estate+1.8%+4.6%+0.7%29.8
72/100⭐⭐⭐⭐⭐
Communication Services+0.7%-2.1%+2.2%21.8
70/100⭐⭐⭐⭐⭐
Basic Materials+0.9%+2.0%-0.3%25.0
60/100⭐⭐⭐⭐
Consumer Defensive+0.8%+1.0%-0.2%28.7
55/100⭐⭐⭐⭐
Utilities-0.7%+2.5%-1.9%25.2
49/100⭐⭐⭐
Energy-0.2%-0.4%-2.4%19.6
42/100⭐⭐⭐
Consumer Cyclical+0.3%-1.6%-4.0%43.3
17/100
Industrials-0.5%-0.1%-8.9%30.4
15/100
Technology-1.6%-0.8%-5.3%42.2
12/100

Sector returns combine NYSE and NASDAQ averages. P/E is the latest blended sector multiple. Sector score ranks each sector vs peers using percentile ranks (not fixed thresholds): 48% 1M + 24% 1W + 8% 1D + 20% P/E (lower P/E ranks higher). Data as of 2026-07-27.